Introduction {#s1}
============

*Staphylococcus aureus* (*S. aureus*) is a collection of multi-lineage Gram-positive cocci that is commensal to humans and is commonly found in the upper respiratory tract of 20\~30% of general population. Yet *S. aureus* is a leading cause of bacteraemia (Stefani et al., [@B37]) in hospitals, and is the most common cause of necrotizing pneumonia, skin, and soft-tissue infections in community (Klevens et al., [@B23]; DeLeo and Chambers, [@B13]).

*S. aureus* contains mobile genetic elements (MGE), comprising of bacteriophages, pathogenicity islands, and transposons that carry genes encoding for antimicrobial resistance and virulence factors. Horizontal gene transfer of these mobile elements may result in strains that are increasingly pathogenic, epidemic, and highly resistant to antibiotics (Tong et al., [@B38]). It has been suggested that methicillin resistant *S. aureus* (MRSA) has evolved from methicillin-susceptible *S. aureus* (MSSA) via acquisition of Staphylococcal cassette chromosome *mec* (SCC*mec* types I--XI) (Baranovich et al., [@B5]; Petersdorf et al., [@B31]). Usually lineages that are important in hospital-acquired infections harbor SCC*mec* III element containing a large number of resistance genes (Ito et al., [@B21]). In contrast, SCC*mec* IV and V are frequently detected in isolates causing community acquired infections, although recently they have also been associated with hospital-acquired infections (Ito et al., [@B22]; Pereira et al., [@B30]).

According to the National Committee for Clinical Laboratory Standards (CLSI), the criteria for identifying MRSA is defined as *S. aureus* harboring *mec*A or *mec*C genes or phenotypically showing minimum inhibitory concentration (MIC) of oxacillin or cefoxitin ≥4 mg/L. The presence of *mec*A gene confers resistance to β-lactam antibiotics but not to penicillins.

MRSA and MSSA may contain *blaZ* gene expressing a β-lactamase enzyme that confers resistance to penicillins only. It is thought that the advantage of the presence of the β-lactam resistance mechanism mediated by *mecA* gene would keep the *bla* system active (Milheiriço et al., [@B27]). Other resistance genes that may be present in *S. aureus* include the multidrug efflux transporter *norA* that confers resistance to a broad spectrum of compounds, comprising of fluoroquinolones, quaternary ammonium compounds, efflux inhibitors such as reserpine, verapamil, and some dyes \[ethidium bromide (EtBr), rhodamine, and acridines\] (Roy et al., [@B34]). Also, proteins of both MFS (major facilitator superfamily) and SMR (the small multidrug resistant) family encode efflux-mediated resistance to a range of structurally unrelated cationic and lipophilic substrates across the cell membrane. In general, MFS encodes genes such as *qac*A, conferring resistance to a range of chemicals including ethidium bromide and chlorhexidine, while *qacB* confers resistance primarily to monovalent organic cations and some divalent compounds. Finally, *smr* genes consisting of *qacC* and *qacD* (Mayer et al., [@B26]) confer resistance to quaternary ammonium compounds (QACs) (Shamsudin et al., [@B35]) but not to chlorhexidine.

It is essential to use biocides and administer antimicrobial agents to reduce the bacterial load and decrease the probability of infections in hospitals. Chlorhexidine has been one of the most frequently used biocides in hospitals, at concentrations ranging from 0.5 to 4%, due to its broad spectrum of activity, tolerability, and safety record. It is commonly used as a skin antiseptic prior to clinical procedures, in dressings, hand disinfections and when bathing patients. The mechanism of action of chlorhexidine is known to be by binding to the negatively charged bacterial cell wall affecting the osmotic equilibrium of the cell.

While MIC and minimum bactericidal concentration (MBC) are commonly used to detect reduced susceptibility to chlorhexidine, there is, nevertheless, neither a defined standardized method nor consensus on the meaning of resistance to this agent (Horner et al., [@B20]). Recently, Morrissey et al. ([@B28]) attempted to define breakpoints for chlorhexidine on the basis of normal distribution of MICs for a given bacterial species, known as the epidemiological cut-off value (ECOFF). ECOFF is described as the upper limit of the normal MIC distribution for chlorhexidine for a specific species and not the likelihood of treatment failure and clinical breakpoints as it is applicable for antibiotics. In general, the advised dose of chlorhexidine usage is several times higher than the MBC, yet, if chlorhexidine concentration reaches sub-lethal levels over time (Bloomfield, [@B7]), those isolates with reduced susceptibility to chlorhexidine will remain viable, survive, and possibly persist.

This study identifies the characteristics of lineages of MRSA and MSSA with reduced susceptibility to chlorhexidine in Kuwaiti hospitals and supports the notion that MSSA should be considered as an important agent of infection among hospitalized patients.

Materials and methods {#s2}
=====================

Bacterial isolates
------------------

One hundred and twenty one MRSA and 56 MSSA were randomly obtained from Kuwaiti *S. aureus* Reference Laboratory in 2013. Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} show the origin of the isolates. Based on the data provided by the MRSA Reference Laboratory all isolates were non-duplicates from single patients. It is noteworthy to mention that our collection contained colonizing as well as infecting isolates. The isolates were confirmed in our laboratory as *S. aureus* by Gram stain, morphology, catalase, and coagulase tests. PBP2 was detected with a slide latex agglutination test (Oxoid, Besingstoke, UK).

###### 

Clinical MRSA and MSSA isolates obtained from hospitals.

  **Hospital**   **No. of MRSA**   **No. of MSSA**
  -------------- ----------------- -----------------
  Adan           10                0
  Amiri          16                2
  Razi           6                 0
  Sabah          30                11
  Armed Forces   0                 7
  Chest          1                 5
  Farwaniya      24                3
  Ibn Sina       0                 1
  Jahra          1                 2
  Maternity      13                4
  Mubaarak       20                17
  Unknown        0                 4
  Total          121               56

###### 

Sources of isolates in this study.

  **Specimen**                    **No. of MRSA**   **No. of MSSA**
  ------------------------------- ----------------- -----------------
  Abscess                         7                 0
  Broncho Alveolar Lavage (BAL)   0                 1
  Blood                           7                 8
  Ear                             5                 3
  Eye                             4                 2
  Fluid                           5                 1
  Groin                           11                3
  High Vaginal Swab               1                 3
  Nasal                           26                8
  Catheter Tip                    2                 1
  Pus                             14                2
  Rectal Swab                     1                 0
  Skin                            12                4
  Sputum                          1                 2
  Suction Tip                     0                 2
  Swab                            6                 1
  Thigh Abscess Pus               0                 1
  Tissue                          2                 2
  Throat swab                     1                 1
  Tracheal                        2                 1
  Umbilical Swab                  1                 1
  Urine                           2                 0
  Wound                           10                5
  Unknown                         1                 4

Susceptibility testing
----------------------

Antibiotic susceptibility testing was performed by disc diffusion method, when applicable, following the Clinical Laboratory Standards Institute ([@B10]) recommendations. The bacterial suspension (the final turbidity of a 0.5 McFarland Standard) was spread over the Mueller-Hinton agar uniformly and the antimicrobial discs were dispensed onto the agar plates using the disk dispenser and incubated overnight at 35°C. The antibiotic agents tested were penicillin (10 μg), cefoxitin (30 μg), ciprofloxacin (5 μg), clindamycin (2 μg) chloramphenicol (30 μg), erythromycin (15 μg), fusidic acid (10 μg), gentamicin (10 μg), kanamycin (30 μg), linezolid (10 μg), mupirocin (200 μg), rifampicin (5 μg), tetracycline (30 μg), teicoplanin (30 μg), tigecycline (15 μg), trimethoprim (5 μg). Inducible clindamycin resistance was detected with double-disk diffusion test (D-test). The diameter of zone of inhibition was measured (mm) and interpreted as recommended by EUCAST ([@B15]) or CLSI guidelines (2014). MIC was determined by agar dilution method following CLSI recommendations for vancomycin (breakpoint \>8 mg/L) and mupirocin (low-level resistance 8--64 mg/L and high-level resistance ≥512 mg/L). Bacterial growth above the breakpoint concentrations confirmed resistance to the relevant antibiotic. *S. aureus* ATCC 25923 was used as the control for disk diffusion and *S. aureus* ATCC 29213 for MIC assays. Isolates that showed resistance to at least three classes of antibiotic were considered as multi-drug resistant (MDR).

Minimum inhibitory concentrations (MIC) and minimum bactericidal concentration (MBC) of chlorhexidine
-----------------------------------------------------------------------------------------------------

Reduced susceptibility to chlorhexidine by MIC and MBC was based on the method described by Morrissey et al. ([@B28]) and Furi et al. ([@B17]). In this study the MIC for chlorhexidine digluconate (CH-; 100 mg/mL in water; C9394; Sigma-Aldrich, St. Louis, MO, USA) was determined using broth microdilution method with doubling concentration of chlorhexidine and starting inocula of 1 × 10^5^ CFU/mL. MBC was determined by subculturing 10 μL from each well without visible bacterial growth on Mueller-Hinton agar plates and incubating them at 37°C for 48 h. The first chlorhexidine dilution plate yielding three colonies or fewer was determined as MBC.

Interpretation of the results was based on the ECOFF, which is the upper limit of the normal MIC distribution for a given antimicrobial agent and a given species. For *S. aureus* and chlorhexidine MIC ≥ 4 mg/L and/or MBC ≥ 30 mg/L have been proposed.

DNA isolation
-------------

Total genomic DNA for PCR and sequencing was extracted using the DNeasy Blood & Tissue Kit (Qiagen Valencia, CA, USA) according to the manufacturer\'s instructions.

Detection of resistance and virulence genes
-------------------------------------------

PCR was performed with HotStar *Taq* polymerase (Qiagen) according to the manufacturer\'s instructions and specific oligonucleotide primers for detection of the following genes: *mecA, mecC*, SCC*mec, agr* locus (*agr-1*~*Sa*~ to *agr-4*~*Sa*~), *lukE*-*lukD, lukS-PV*, and *lukF-PV, norA, qacA/B, qacC/qacD, qacG, qacH, blaZ, mupA, vanA, aac6*′*/aphD* (Oligonucleotide primers are listed in Supplement [1](#SM1){ref-type="supplementary-material"}). Amplified PCR products were purified with Qiagen purification kit (Qiagen Valencia, CA, USA) according to the manufacturer\'s instructions and both strands were sequenced by automated AB13100 DNA sequencer (Applied Biosystems, Carlsbad, CA, USA) system. The BLAST program of the National Centre for Biotechnology Information (<http://www.ncbi.nlm.nih.gov>) was used to search and compare databases for similar nucleic acid sequences.

*spa* typing
------------

Based on the sequence analysis of polymorphic region X of protein A, a highly effective subtyping method for *S. aureus* is *spa* typing (Deurenburg et al., [@B14]). Amplification and sequencing of the variable region of the protein A gene, the sequence analysis and *spa*-type assignment were carried out as previously described (Harmsen et al., [@B18]). The X region of the *spa* gene was amplified by PCR with primers 1095F (5′-AGACGATCCTTCGGTGAGC-3′) and 1517R (5′-GCTTTTGCAATGTCATTTACTG-3′). DNA sequences were obtained with an ABI sequencer (Applied Biosystems). *spa* sequence types were determined with the database accessible via <http://spa.ridom.de/> using BioNumerics version 7.1 (Applied Maths, Ghent, Belgium). The node distances between the spa types was calculated by minimum spanning tree method using Dice correlation (BioNumerics v.7.1.)

Multi-locus sequence typing (MLST)
----------------------------------

Genomic DNA was extracted from overnight cultures and MLST was carried out according to the protocol for *S. aureus* on the MLST website (<http://www.mlst.net>). The fragments of seven housekeeping genes (Supplement [1](#SM1){ref-type="supplementary-material"}) *arcC, aroE, glpF, gmk, pta, tpi*, and *yqiL* were amplified and sequenced. Nucleotide sequences were aligned and trimmed using Bionumerics 7.1 software (Applied Maths, Ghent, Belgium). Allele numbers and sequence types (STs) were assigned by submitting sequences to the MLST website. MLST was performed on the isolates that contained *qac*A/B/C and on those isolates that showed reduced susceptibility to chlorhexidine.

Pulse-field gel electrophoresis (PFGE)
--------------------------------------

Clinical isolates were typed by Pulse-Field gel electrophoresis (PFGE) with the CHEF-DR II electrophoresis cell after digestion with SmaI restriction endonuclease enzyme (Bannerman et al., [@B4]). The running parameters were as follows: initial pulse 5 s, final pulse 40 s, at 6 V/cm for 20 h at 14°C. The gels were stained with ethidium bromide and scanned. Profiles were analyzed by the unweighted pair method with arithmetic average (UPGMA) using BioNumerics v.7.1. The development of the algorithms necessary for the comparison of fingerprinting profiles of isolates was based on the Dice correlation coefficient. The hierarchic Cluster analysis and phylogenetic trees were subsequently analyzed with an optimization of 1.5% and a tolerance of 1.5%. Isolates were considered to belong to the same PFGE clone if their Dice similarity index was ≥85%.

Qualitative real-time PCR amplification of *qac* genes
------------------------------------------------------

Real time qPCR was performed on *qac*A/B positive isolates. The total RNA was extracted using Qiagen RNeasy Kit (Qiagen Valencia, CA, USA) and cDNA was synthesized (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems) and used as a template for qPCR amplification using SYBR Green method (EvaGreen qPCR Mix Plus, Solis Biodyne) using the primers described previously (Furi et al., [@B17]). Two TaqMan probes with two different fluorophores at the 5 = end and a minor groove binder (MGB) at the 3 = end (Applied Biosystems, United Kingdom) were used in order to distinguish between *qacA* and *qacB*. Qualitative real-time PCRs were performed in a Light Cycler 480 system (Roche Diagnostics, Germany). Melt curve analysis was performed along with the amplification protocol to determine if non-specific products were amplified during the reaction. The Ct (cycle threshold) value and melting curve analysis was used to confirm the presence of one peak and one product. Further agarose gel analysis (3%) was performed to confirm the amplification of a single PCR product.

Statistical analysis
--------------------

*P*-values were calculated using the *t*-test to determine whether differences between variants were significant using the unpaired two-tailed Mann-Whitney *U* (IBM SPSS version 23).

Results {#s3}
=======

Characterization of *S. aureus* isolates
----------------------------------------

All 121 MRSA isolates were *mecA* positive and consisted of 1 (0.8%) SCC*mec* II, 26 (21.5%) SCC*mec* III, 84 (69.4%) SCC*mec* IV, and 10 (8.3%) SCC*mec* V. *mec*C was not detected. Sixty-five (54%), 18 (15%), and 10 (8%) contained *agr-1*~*Sa*~, *agr-2*~*Sa*~, and *agr-3*~*Sa*~ respectively, while 28 (23%) were *agr* negative. *pvl* was present in 45% (*n* = 55) while 39% (*n* = 47) contained *lukE*-*lukD* (Figure [1](#F1){ref-type="fig"}).

![The percentage of virulence genes detected in MSSA isolates is higher than MRSA.](fmicb-08-01359-g0001){#F1}

Among MSSA, *agr-1*~*Sa*~, *agr-2*~*Sa*~, and *agr-3*~*Sa*~ were present in 27 (48%), 14 (25%), and 15 (27%) of the isolates respectively. *agr-4*~*Sa*~ was not detected. 86% (*n* = 48) contained *pvl* and 96.4% (*n* = 54) contained *lukE*-*lukD* (Figure [1](#F1){ref-type="fig"}).

Spa typing
----------

Among the MRSA isolates, 36 known and two unknown *spa* types were identified: *spa* types t044 and t223 had the highest prevalence at 9.1% (*n* = 11) and 8.3% (*n* = 10) respectively. Among MSSA there were 37 known and 1 unknown *spa* types, t945 (9% *n* = 5 isolates) was the most prevalent. Altogether there was a two-fold variation in *spa* types among MSSA (38/56) vs. MRSA isolates (38/121) (68 vs. 31%) (*p* = 0.015). The common *spa* types shared among MRSA and MSSA were t002, t127, t223, t267, t304, t306, t688, t945, t3244, and t4867.

Figure [2](#F2){ref-type="fig"} shows the node distances between spa types based on clustering by minimum spanning tree method using Dice correlation (BioNumerics v.7.1.). Node size is proportional to spa type frequency and line length is proportional to the number of mutational steps between the types.

![Relationship between *spa* types of MSSA and MRSA isolates in this study. Node size is proportional to spa type frequency and line length is proportional to the number of mutational steps between the types. The node distances between the spa types was calculated by minimum spanning tree method using Dice correlation (BioNumerics v.7.1.). Based on the default setting of 1%, distance intervals are created that are converted into distance units. For example two entries when having a similarity of 99.6% will have a distance of 0 (interval 100--99% = distance 0). Two entries that have a similarity of 98.7% will have a distance of 1 (interval 99--98% = distance 1).](fmicb-08-01359-g0002){#F2}

MRSA- *pvl* (+) isolates belonging to *spa* types t044 (*n* = 7), t019 (*n* = 5), t852 (*n* = 5) were the most prevalent, followed by t105 (*n* = 3); t002, t005, t945, t2518, and t3107 (*n* = 2 each); t024, t032, t086, t127, t548, t657, t690, t902, t1347, t1560, t1752, t3244, t4867, and t7358 (*n* = 1 each).

*pvl* (+) MSSA isolates were t945 (*n* = 4), t267 (*n* = 3), and t4045 (*n* = 3) followed by t127, t304, t306, t359, t688, t3841, and t4867 (*n* = 2 each); and t002, t015, t021, t062, t084, t085, t166, t315, t346, t349, t376, t521, t701, t710, t1109, t1727, t2393, t2526, t2663, t3244, t3643, t7760, t9787 (*n* = 1 each).

Detection of biocide resistance genes
-------------------------------------

Figure [3](#F3){ref-type="fig"} shows the prevalence of combinations of biocide resistance gene observed in this study. *qac* genes were identified in 15 MRSA isolates (12.3%) of which 1 contained *qacC* (*smr*). Based on real time qPCR (Supplement [2](#SM2){ref-type="supplementary-material"}), 13 isolates harbored *qacA* and 1 contained *qacB. norA* was present in 82.6% (*n* = 100), and *blaZ* in 94.2% (*n* = 114). Among MSSA, only 3 isolates (5.4%) harbored *qacA* gene. *norA* was present in 83% (*n* = 47), and *blaZ* in 91% (*n* = 51). We could not identify any statistically significant differences between the occurrences of either *blaZ* or *norA* in MRSA and MSSA isolates, however, MRSA was more likely to contain *qacA* gene than MSSA (*p* \< 0.05).

![In this figure the combination of biocide resistance genes observed among the isolates has been shown.](fmicb-08-01359-g0003){#F3}

Antimicrobial resistance patterns
---------------------------------

Table [3](#T3){ref-type="table"} shows the percentage of resistant isolates to the tested antimicrobial agents. For MRSA all isolates were resistant to oxacillin and cefoxitin and susceptible to rifampicin, tigecycline, teicoplanin, and linezolid. There were two vancomycin resistant MRSA isolates with MIC = 16 mg/L, typed as: (R15): ST239-MRSA-III/t860/*pvl*(--) *qacA* (+) and (S52): ST772-MRSA-V/t4867/*pvl*(+)*nor*A(+)*qacC*(+) (Table [4](#T4){ref-type="table"}). PCR experiments using *van*A primers did not yield any bands. All MSSA isolates were susceptible to rifampicin, mupirocin, linezolid, tigecycline, teicoplanin, oxacillin, and cefoxitin. All isolates that were resistant to both gentamicin and kanamycin contained *aac6*′*/aphD* gene encoding the aminoglycoside-modifying enzymes. 44.6% of MSSA and 62.8% of MRSA were MDR.

###### 

Percentage of resistance to each antimicrobial agent tested.

  **Antimicrobial agent**                           **No. resistant MRSA (%)**   **No. resistant MSSA (%)**
  ------------------------------------------------- ---------------------------- ----------------------------
  Penicillin                                        121 (100)                    47 (84)
  Cefoxitin                                         121 (100)                    0
  Ciprofloxacin                                     40 (33)                      14 (25)
  Chloramphenicol                                   2 (1.7)                      0
  Clindamycin (C)[^a^](#TN1){ref-type="table-fn"}   35 (29)                      16(29)
  Clindamycin (I)[^b^](#TN2){ref-type="table-fn"}   13 (11)                      0
  Erythromycin                                      49 (40)                      16 (29)
  Fusidic Acid                                      24 (20)                      5 (9)
  Gentamicin                                        41 (34)                      38 (68)
  Kanamycin                                         52 (43)                      27 (48)
  Mupirocin (HLR)[^c^](#TN3){ref-type="table-fn"}   4 (3.3)                      0
  Mupirocin (LLR)[^d^](#TN4){ref-type="table-fn"}   11 (9)                       0
  Tetracycline                                      34 (28)                      16 (29)
  Trimethoprim                                      34 (28)                      7 (7)
  Vancomycin                                        2 (1.7)                      0

\(C\) Constitutive resistance to clindamycin;

\(I\) Inducible resistance to clindamycin;

(HLR) High level resistance to mupirocin;

*(LLR) Low level resistance to mupirocin*.

###### 

Typing characteristics and antimicrobial profile of qac(+) MRSA and MSSA and qac(--) isolates with reduced susceptibility to chlorhexidine.

  **Key**   **ST**   **Spa**   **SCC*mec***   **Specimen**        **Hospital**               ***qac***   ***nor*A**   ***bla*Z**   ***pvl***   ***LUKED***   ***agr***   **CHX MBC(mg/L)**   **Antibiotic resistance**
  --------- -------- --------- -------------- ------------------- -------------------------- ----------- ------------ ------------ ----------- ------------- ----------- ------------------- -----------------------------------------------------
  R-3       22       t4326     IV             Groin               MUBARAK (ICU)              --          \+           \+           --          --            1           30                  Pen, Gen, Kan, Ery, Cli ^I^, Tri, Cip
  R-4       22       t852      IV             Nasal               MUBARAK (ICU)              --          \+           \+           \+          --            1           30                  Pen, Gen, Kan, Ery, Cli ^C^, Tri, Cip
  R-12      22       t852      IV             Eye                 MATERNITY                  --          \+           \+           \+          --            1           30                  Pen, Gen, Kan, Tri
  R-13      22       t902      IV             Nasal               SABAH (PICU)               --          --           \+           \+          --            1           30                  Pen, Gen, Kan, Tri
  R-15      239      t860      III            Groin               MUBARAK (Surgical)         A           --           \+           --          \+            1           15                  Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip, Van
  R-21      239      t945      III            Nasal               SABAH (ICU)                A           --           \+           --          \+            1           30                  Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^LLR^
  R-38      239      t945      III            Catheter Tip        SABAH (Internal)           A           --           \+           --          --            1           7.5                 Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^LLR^
  R-45      239      t860      III            Groin               MUBARAK (Surgical)         A           --           \+           --          \+            1           30                  Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip, Mup
  R-53      239      t860      III            Blood               MATERNITY (NICU)           A           \+           \+           --          \+            1           30                  Pen, Gen, Kan, Ery, Cli^C^, Tri, Fus, Cip,Mup^HLR^
  R-62      5        t002      II             Nasal               AMIRI (Internal)           --          \+           \+           --          \+            2           0.94                Pen, Gen, Kan, Ery, Cli^C^, Cip, Mup^HLR^
  R-67      80       t044      IV             Abscess             AMIRI                      --          \+           \+           \+          \+            1           1.875               Pen, Kan, Tet, Fus, Mup^HLR^
  R-84      239      t945      III            Blood               SABAH (ICU)                A           \+           \+           \+          \+            1           60                  Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip, Mup^LLR^
  R-87      80       t044      IV             Tissue              SABAH (PICU)               --          \+           \+           \+          \+            1           1.875               Pen, Gen, Kan, Ery, Cli ^I^, Tri, Cip, Mup^LLR^
  R-101     239      t945      III            Skin                SABAH (Internal)           A           \+           \+           \+          \+            1           30                  Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip
  R-102     239      t860      III            Nasal               MUBARAK (Surgical)         A           --           \+           --          \+            1           7.5                 Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^LLR^
  R-103     239      t860      III            Pus                 MUBARAK (Liver dialysis)   A           --           \+           --          \+            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^HLR^
  R-104     239      t860      III            Groin               MUBARAK (Surgical)         A           --           \+           --          \+            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^LLR^,
  R-105     239      t945      III            Groin               SABAH (SICU)               A           --           \+           --          --            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^LLR^
  R-106     239      t860      III            Nasal               RAZI (Isolation Unit)      A           --           \+           --          \+            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup ^LLR^
  R-107     239      t945      III            Tracheal            SABAH (Surgical)           B           --           \+           --          \+            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip,Mup^LLR^
  R-110     239      t945      III            Sputum              RAZI (Surgery)             --          \+           \+           --          \+            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip, Mup^LLR^
  R-111     239      t945      III            Fluid               SABAH (Outpatient)         --          \+           \+           --          \+            1           0.94                Pen, Gen, Kan, Ery, Cli^C^, Tet, Fus, Cip, Mup^LLR^
  R-113     22       t2518     IV             Pus                 FARWANIYA (Surgical)       A           --           \+           \+          --            1           0.94                Pen, Gen, Kan, Cip
  S-7       239      t945      MSSA           Skin                SABAH (Internal)           A           \+           \+           \+          \+            1           30                  Pen, Gen, Kan, Tob, Cip, Tri
  S-19      1        t127      MSSA           High Vaginal Swab   MATERNITY                  --          \+           \+           \+          \+            3           30                  Pen, Kan
  S-22      88       t4045     MSSA           Blood               MUBARAK                    --          \+           \+           \+          \+            3           60                  Pen, Kan, Tob
  S-23      97       t359      MSSA           Blood               MUBARAK                    --          \+           \+           \+          \+            1           30                  Pen, Kan, Tob
  S-24      5        t4867     MSSA           Ear                 SABAH                      --          \+           \+           \+          \+            2           60                  Pen, Gen, Kan, Tob, Tri
  S-25      1        t127      MSSA           Nasal               SABAH (Internal)           --          \+           \+           \+          \+            3           60                  Pen, Gen, Kan, Tob
  S-27      22       t223      MSSA           Eye                 MUBARAK (Pediatric)        --          \+           \+           --          \+            1           30                  Pen, Tob, Kan
  S-32      5        t002      MSSA           Skin                FARWANIYA (Pediatric)      --          \+           \+           \+          \+            2           30                  Cip, Gen, Kan,Tob
  S-35      15       t084      MSSA           High Vaginal Swab   MUBARAK                    --          \+           \+           \+          \+            2           30                  Pen, Gen, Kan, Tob
  S-41      932      t304      MSSA           Sputum              SABAH (ICU)                --          \+           \+           \+          \+            3           30                  Pen, Gen, Kan, Tob
  S-42      672      t003      MSSA           Blood               FARWANIYA                  --          --           \+           --          \+            1           \>60                Pen, Kan, Tob, Tri
  S-43      965      t062      MSSA           Sputum              --                         --          --           --           \+          \+            2           30                  Pen, Gen, Kan, Tob
  S-44      239      t945      MSSA           Groin               --                         --          --           \+           \+          \+            1           \>60                Pen, Gen, Kan, Tob, Ery, Cip
  S-46      5        t688      MSSA           Nasal               ICU                        --          --           --           \+          \+            2           60                  Pen, Gen, Kan, Tob,
  S-47      217      t3244     IV             Blood               AMIRI(ICU)                 --          \+           \+           --          --            1           60                  Pen, Gen, Kan, Tob, Ery, Cip, Tri
  S-48      239      t945      MSSA           Groin               SABAH (Surgical)           --          --           \+           \+          \+            1           60                  Pen, Gen, Kan, Tob, Ery, Cip
  S-49      97       t359      MSSA           High Vaginal Swab   MATERNITY                  --          --           --           \+          \+            1           30                  Kan, Tob, Tri
  S-50      96       t521      MSSA           Suction tip         ARMED FORCES               --          --           \+           \+          \+            3           30                  Pen, Gen, Kan, Tob, Cip, Tri,
  S-51      5        t4867     MSSA           Tracheal            SABAH (ICU)                --          \+           \+           \+          \+            2           60                  Pen, Gen, Kan, Tob, Tri
  S-52      772      t4867     V              Nasal Swab          SABAH (Surgical)           C           \+           \+           \+          \+            2           30                  Pen, Gen, Kan, Tob, Cip, Tri, Van
  S-53      34       t166      MSSA           Umbilical Swab      MUBARAK(NICU)              --          \+           \+           \+          \+            3           30                  Pen, Kan, Tob, Tri
  S-56      239      t945      MSSA           Groin               SABAH (Surgical)           A           \+           \+           \+          \+            1           30                  Pen, Gen, Kan, Tob, Ery, Cip
  S-57      239      t945      MSSA           Swab                SABAH (Surgical)           A           \+           \+           \+          \+            1           7.5                 Pen, Gen, Kan, Tob, Cip

*Cip, Ciprofloxacin; Chl, Chloramphenicol; CHX MBC, Chlorhexidine Minimum Bactericidal Concentration; Cli^C^, Constitutive resistance to clindamycin; Cli^I^, Inducible resistance to clindamycin; Ery, Erythromycin; Fus, Fusidic Acid; Gen, Gentamicin; ICU, Intensive Care Unit; Kan, Kanamycin; Mup^HLR^, High level resistance to mupirocin; Mup^LLR^, Low level resistance to mupirocin; NICU, Neonatal Intensive Care Unit; Pen, Penicillin; PICU, Pediatric Intensive Care Unit; SICU, Surgical Intensive Care Unit; Tet, Tetracycline; Tri, Trimethoprim; Van, Vancomycin*.

Mupirocin resistance in MRSA
----------------------------

We did not find any MSSA isolates resistant to mupirocin. However, 4 MRSA isolates showed high-level and 11 showed low-level resistance (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). The presence of *mup*A gene was detected by PCR generating a 1.65 kb intragenic fragment for both resistant phenotypes. The four high-level mupirocin-resistant isolates were typed as (R-45, R-103): ST239-MRSAIII/t860/*qacA*(+), (R-53): ST239-MRSAIII/t860/*qacA*(+)/*nor*A(+), and (R-62): ST5-MRSAII/t002/*nor*A(+).

11 MRSA low-level mupirocin-resistant isolates were typed as (R-21, R-38, R-105): ST239-MRSAIII/t945/*qac*A(+), (R-84): ST239-MRSAIII/t945/*norA*(+)/*qac*A(+), (R-87): ST80-MRSAIV/t044/*nor*A(+), (R-102, R-104, R-106): ST239-MRSAIII/t860/*qac*A(+), (R-107): ST239-MRSAIII/t945/*qac*B(+), (R-110, R-111) ST239-MRSAIII/t945/*norA*(+). These isolates were collected from a variety of specimens from different hospitals (Table [4](#T4){ref-type="table"}).

*qac* genes, MLST, and chlorhexidine
------------------------------------

For MRSA, MIC range was 0.5--2 mg/L with MIC~50~ = 1 mg/L and MIC~90~ = 2 mg/L, MBC range was 1--30 mg/L with MBC~50~ = 4 mg/L and MBC~90~ = 30 mg/L. For MSSA, MIC range was 0.5--60 mg/L with MIC~50~ = 1 mg/L and MIC~90~ = 2 mg/L. MBC range was from 4 to \>60 mg/L with MBC~50~ = 30 mg/L and MBC~90~ = 60 mg/L. These results suggest that although more MRSA than MSSA isolates harbored *qac* genes (*n* = 15 vs. *n* = 3), MBC~90~ was higher for MSSA implying that the presence of *qac*A might not be significant in reducing susceptibility or prompting higher MBC to chlorhexidine.

MLST and PFGE for *qac*(+) and those MRSA and MSSA isolates with MBC ≥ 30 mg/L are shown in Figure [4](#F4){ref-type="fig"} and Table [4](#T4){ref-type="table"}. Based on the suggested ECOFF, the reduced susceptibility to chlorhexidine did not exclusively depend on the presence of *qac* genes, however, MBC of chlorhexidine was higher for those *qac*A(+) isolates obtained from blood. For chlorhexidine, the median of MBC was statistically greater than the median of MIC (*p*-value \< 0.0001). The median of MIC and MBC for *qac*A(+) isolates were higher than *qac*A(--) isolates (*p*-value 0.36 and 0.6, respectively). Results were analyzed using the unpaired two-tailed Mann-Whitney *U* (IBM SPSS version 23).

![PFGE profiles of *qac*(+) MRSA and MSSA and *qac*(--) isolates with reduced susceptibility to chlorhexidine. The hierarchic Cluster analysis and phylogenetic tree after digestion with *Sma*I is shown. PFGE banding patterns were analyzed using DICE/UPGMA with an optimization of 1.5% and a tolerance of 1.5% generated by BioNumerics software (v.7.1). The percentage of similarities between the clusters are shown.](fmicb-08-01359-g0004){#F4}

Moreover, there were *qac*A(+) isolates that did not display high MBC (MBC ≤ 7.5 mg/L) (Table [4](#T4){ref-type="table"}) as well as *qac*A(--) MSSA isolates with reduced susceptibility to chlorhexidine (including S-53: ST34-MSSA/t161 isolated from an infected umbilical cord of a neonate, S-48: ST239-MSSA/t945, S-46: ST5-MSSA/t688, S-51: ST5-MSSA/t4867, S-42:ST672-MSSA/t003, S-19:ST1-MSSA/t127, S-35:ST15-MSSA/t084, S-22:ST88/t4045, S-50: ST-96/t521, S-49: ST97/t359, S-41: ST932-MSSA/t304 and S-43: ST965-MSSA/t062). Likewise *qac*A(--) MRSA isolates including ST22-MRSA-IV (with variable *spa* types), ST239-MRSA-III and ST217-MRSA-IV showed reduced susceptibility to chlorhexidine (Table [4](#T4){ref-type="table"}, Figure [4](#F4){ref-type="fig"}).

The only *qac*B(+) isolate (R-107) in our collection was susceptible (MBC ≤ 1 mg/L) whereas the only *qac*C(+) isolate (S-52) showed reduced susceptibility to chlorhexidine (MBC = 30 mg/L).

PFGE analysis
-------------

PFGE results for isolates with reduced susceptibility to chlorhexidine and those containing *qac* genes are shown in Figure [4](#F4){ref-type="fig"}. Cluster analysis was performed and phylogenic tree was prepared using dice similarities and unweighted matched-pair group which demonstrated diversity among the isolates. It also showed that none of the MSSA and MRSA isolates shared identical PF patterns.

Discussion {#s4}
==========

This is the first study to identify heterogeneous genotypes of *qac* and non-*qac* harboring MRSA and MSSA with reduced susceptibility to chlorhexidine in Kuwait. The MBC~90~ of chlorhexidine for MSSA isolates was higher than that of MRSA, even though the number of isolates containing *qac* genes was higher in the MRSA group (*n* = 15 vs. *n* = 3). These results suggest that elements other than *qac* genes may be important for reducing susceptibility to chlorhexidine. One factor to consider would be the expression of the *agr* quorum-sensing system which is already known to influence virulence factor production but which may also affect antimicrobial resistance and metabolism through its interaction with other staphylococcal gene regulators (Tseng et al., [@B39]). In our study virulence factors were generally more prevalent in MSSA. Forty-five percentage MRSA and 86% of MSSA contained *pvl* while 39% of MRSA and 96.4% of MSSA contained *lukE*-*lukD* genes. Similar to a previous report (Warren et al., [@B41]) we also observed *qac*A(+) MRSA isolates were more likely to exhibit mupirocin resistance.

In this study the predominant resistance gene was *blaZ* which was present in 94.2% of MRSA and 91% of MSSA usually in combination with other biocide genes. Thirteen MRSA and only 3 MSSA isolates (5.4%) harbored *qac*A and 16 out of 18 (89%) *qac*(+) isolates were typed as ST239. ST239-MRSA-SCC*mec*III, also known as the hospital-acquired Brazilian/Hungarian clone, is one of the most successful lineages in the world owing its high rate of prevalence to an enhanced ability to form biofilm and a tendency to acquire genes that confer resistance to different classes of antimicrobials (Amaral et al., [@B3]). The most common reported spa type associated with ST239-MRSA is the ancestral spa type t037 (the plesiomorphic state) (Harris et al., [@B19]), but other spa types have also been linked to ST239. In this study spa types t945 and t860 were common between ST239-MRSA and ST239-MSSA however their PFGE banding patterns were dissimilar. In addition to ST239, other common lineages between MSSA and MRSA were ST5 and ST22. Similar observation but with different STs have been noted before (Crisóstomo et al., [@B12]). To determine whether these strains lost or gained Scc*mec* over time will require more genetic analysis.

Other MRSA lineages with reduced susceptibility to chlorhexidine were ST217, a single-locus variant of EMRSA-15, which is prevalent in Europe and India (Qi et al., [@B32]; Vignaroli et al., [@B40]; Bouchiat et al., [@B9]) and has been also detected from food-stuffs of animal origin (Lozano et al., [@B25]). Also the highly transmissible ST772-MRSA-V/t4867 (the Bengal clone) (Afroz et al., [@B2]) which has been detected in different countries (Fuentes et al., [@B16]; Nadig et al., [@B29]; Shore et al., [@B36]) including Kuwait (Boswihi et al., [@B8]). However, this is the first time *qac*C and reduced susceptibility to chlorhexidine has been identified in this infectious clone. *qac*C is a mobile gene that can be transferred between plasmids without the aid of insertion sequences or transposases also known as "DSO-gene-SSO" element (Wassenaar et al., [@B42]).

We also observed high MBC for chlorhexidine among MSSA lineages including ST34 and ST5; commonly linked to mother-to-infant transmission (Achermann et al., [@B1]; Benito et al., [@B6]), ST88-MSSA, a prevalent colonizer in Portugal and China (Qiao et al., [@B33]), ST97 (associated with food producing animals) (Lozano et al., [@B24]) and among other less reported lineages: ST96, ST932, and ST965.

Nevertheless in Staphylococci, *qac* genes may be associated with ecologically successful genetic lineages to retain a high level of endemicity and or epidemicity. In environments where biocide delivery is compromised, whether in the community or in hospitals, the possession of biocide resistance genes (*qac*) may contribute to clonal expansion (Cooper et al., [@B11]). Yet, high rate of the putative virulent *pvl* gene in MSSA clones with reduced susceptibility to chlorhexidine should be monitored with vigilance as they may lead to poor prognosis in patients.

Our overall conclusion from this study is that clinical MSSA isolates with reduced susceptibility to chlorhexidine are genetically diverse. Since MSSA infections are important globally and are not just a local problem, the typing information can be used to evaluate the significance of distribution of these lineages and their clonal relationships in other countries.
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